IceCure Medical Partners with Adventist Health for Breast Cancer Cryoablation Study

IceCure Medical Collaborates with Adventist Health for ChoICE Study

IceCure Medical Ltd., a pioneer in minimally invasive cryoablation technology, recently announced a significant partnership with Adventist Health Glendale, marking the first U.S. clinical site selected for its post-marketing ChoICE Study. This pivotal study aims to evaluate the efficacy of IceCure's ProSense® system in treating low-risk breast cancer among patients aged 70 and older.

The ChoICE Study emerges following the U.S. Food and Drug Administration's (FDA) marketing authorization of ProSense® in October 2025. Adventist Health Glendale has secured approval from the Institutional Review Board (IRB), allowing it to enroll patients. Led by Dr. Dennis Holmes, a nationally recognized breast surgery authority and researcher in cryoablation, this site is poised to advance clinical knowledge and treatment capabilities for low-risk breast cancer patients.

Enhancing Treatment Options

"The addition of Adventist Health Glendale and Dr. Holmes to our ChoICE Study team is a substantial step forward for IceCure," said Eyal Shamir, CEO of IceCure Medical. The partnership signifies IceCure's commitment to expanding access to the promising treatment methods offered by cryoablation—a less invasive alternative to traditional surgical tumor removal. Dr. Holmes underscores the necessity of balancing effective cancer control with patients' quality of life, especially for older patients facing early-stage breast cancer.

The ChoICE Study aims to gather real-world data, incorporating 400 patients across various U.S. sites. This data is expected to bolster the clinical adoption of ProSense® and broaden treatment access for those with biologically low-risk tumors measuring 1.5 cm or less. Additionally, it facilitates the combined application of cryoablation and endocrine therapy, offering a comprehensive treatment approach.

A Commitment to Evidence-based Care

As Dr. Holmes elaborates, the ChoICE Study aims to meticulously explore the integration of cryoablation into standard breast cancer management, assessing follow-up healthcare and adherence to prescribed therapies. The opportunity to include more than 30 sites in this study allows for extensive patient enrollment and the chance to provide ProSense® to patients who may not be participating in the ChoICE Study, amplifying the overall impact of the trial.

ProSense®’s FDA approval has already prompted interest among patients looking for minimally invasive cancer treatment options that can lead to faster recoveries and less time in pain.

IceCure Medical's Pioneering Journey

Founded with the mission to innovate cancer treatment, IceCure Medical has established itself as a leader in cryoablation technology, focusing on treatments for a variety of cancers, including breast, kidney, bone, and lung. The ProSense® system, characterized by its use of liquid nitrogen, enables the efficient destruction of both benign and malignant tumors, positioning IceCure at the forefront of medical technology advancements.

Adventist Health Glendale has long been recognized for its commitment to clinical excellency. With a comprehensive range of services and over 500 inpatient beds, the medical center embodies the highest standards of patient care and safety—a perfect backdrop for the ChoICE Study.

By examining cryoablation's effectiveness, the ChoICE Study may very well redefine treatment paradigms for older breast cancer patients, promoting a future where minimally invasive options become mainstays in oncological practice. The field of breast cancer treatment stands to gain much from this innovative collaboration, as IceCure Medical and Adventist Health Glendale pave the way towards enhanced patient outcomes, offering hope and new possibilities in the fight against cancer.

In conclusion, the partnership between IceCure Medical and Adventist Health Glendale exemplifies a progressive step in the ongoing effort to provide smarter, safer, and more assertive treatment opportunities for breast cancer patients, signaling both a bright future for research and development in minimally invasive treatments and an optimistic outlook for those diagnosed with breast cancer.